BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT
Relay Therapeutics, Inc. (NASDAQ:RLAY) is one of the 13 Best Long-Term Penny Stocks to Buy According to Analysts.
Relay Therapeutics Inc. (RLAY)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Point72 Asset Management Steve Cohen | 10,827,067 | $28,366,917 | +580% | 0.06% |
| 2. | Casdin Capital Eli Casdin | 9,098,574 | $23,838,264 | +2% | 1.95% |
| 3. | Tang Capital Management Kevin C. Tang | 8,068,058 | $21,138,312 | 1.17% | |
| 4. | Kynam Capital Derrick Tang | 3,063,292 | $8,025,825 | +207% | 0.67% |
| 5. | Millennium Management Israel Englander | 2,942,875 | $7,710,333 | +15% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 25,000 | $500,000.00 | 403,082 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 1,021,952 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 25,000 | 2020-07-20 | Filing | |
| $20.00 | 25,000 | $500,000.00 | 25,000 | 2020-07-20 | Filing | |
| $20.00 | 10,000 | $200,000.00 | 10,000 | 2020-07-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.00 | 10,739 | $32,217.00 | 390,081 | 2025-04-30 | Filing | |
| $3.17 | 1,364 | $4,323.88 | 400,820 | 2025-04-28 | Filing | |
| $3.00 | 12,943 | $38,829.00 | 355,376 | 2025-04-30 | Filing | |
| $3.23 | 3,558 | $11,492.34 | 368,319 | 2025-04-29 | Filing | |
| $3.17 | 981 | $3,109.77 | 371,877 | 2025-04-28 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 493 | $1,706 | 0% |
News See All
13 Best Long-Term Penny Stocks to Buy According to Analysts
On June 18, Société Générale's Subadra Rajappa appeared on CNBC to talk about her expectations from the Fed.
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Steve Wagner’s Substack. In this article, we will summarize the bulls’ thesis on RLAY. Relay Therapeutics, Inc.
Relay Therapeutics' RLY-2608 Shows Promising 11-Month PFS in Breast Cancer
On Monday, Relay Therapeutics Inc.
10 Best Low Priced Biotech Stocks to Buy Now
On May 8, Michael Yee, Senior Biotech Analyst at Jefferies, appeared on CNBC to discuss how tariffs and policy risks are pressuring the biotech industry, while simultaneously iterating that low valuations...
Relay Therapeutics, Inc. (RLAY): A Bull Case Theory
We came across a bullish thesis on Relay Therapeutics, Inc. (RLAY) on Substack by Steve Wagner. In this article, we will summarize the bulls’ thesis on RLAY. Relay Therapeutics, Inc.
11 Most Promising Penny Stocks According to Analysts
Solus’ Dan Greenhaus, and Invesco's Brian Levitt together appeared on CNBC's 'Closing Bell' on April 15 to talk about tariffs, market uncertainty, and risk concerns.
13 Best Biotech Penny Stocks to Buy According to Hedge Funds
Peter Marks's departure from the FDA has left innovators concerned regarding the current state of the review program at the FDA. Marks had impacts on two key areas.
10 Stocks Under $10 that Will Triple
As we delve into the discussion on stocks that will triple, we must shed light on the U.S.
Top 9 AI Ratings and News Updates on Wall Street’s Radar
Despite AI's potential to transform our lives for the better, security threats associated with the technology continue to make headlines.
Billionaire Hedge Funds
